Ampio Pharmaceuticals Inc Stock News

Ampio Pharmaceuticals Inc. (AMEX:AMPE) shares, rose in value on Friday, 11/26/21, with the stock price down by -4.13% to the previous days close as strong demand from buyers drove the stock to $1.16. Actively observing the price movement in the last trading, the stock closed the session at $1.21, falling within a range of $1.12 Analysts Predict An Ampio Pharmaceuticals Inc. (AMEX: AMPE) Spike? Read More »

Zacks Investment Research lowered shares of Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) from a buy rating to a hold rating in a research note released on Tuesday, Zacks.com reports. According to Zacks, Ampio Pharmaceuticals, Inc. develops proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. Principal products offered by the Company []

Northern Trust Corp increased its holdings in Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) by 431.6% during the second quarter, HoldingsChannel reports. The institutional investor owned 1,850,262 shares of the specialty pharmaceutical companys stock after acquiring an additional 1,502,216 shares during the quarter. Northern Trust Corps holdings in Ampio Pharmaceuticals were worth $3,090,000 at the end of the []

ENGLEWOOD, Colo., Nov. 23, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call with its CEO and

The trading price of Ampio Pharmaceuticals Inc. (AMEX:AMPE) closed lower on Monday, November 22, closing at $1.14, -8.06% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

In the last trading session, 1.15 million shares of the Ampio Pharmaceuticals Inc. (AMEX:AMPE) were traded, and its beta was 1.57. Most recently the companys share price was $1.24, and it changed around $0.09 or 7.83% from the last close, which brings the market valuation of the company to $232.40M. AMPE currently trades at a Its Easy To Bet On Ampio Pharmaceuticals Inc. (AMEX: AMPE) For Economic Progress Over The Impending Months Read More »

ENGLEWOOD, Colo., Nov. 22, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, today announced that Mike Macaluso is taking a one-year medical leave of

LPL Financial LLC grew its stake in shares of Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) by 73.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 108,564 shares of the specialty pharmaceutical companys stock after purchasing an additional 45,914 shares during the quarter. LPL Financial []

Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research report issued on Wednesday, Zacks.com reports. The firm presently has a $1.50 target price on the specialty pharmaceutical companys stock. Zacks Investment Researchs price target suggests a potential upside of 30.43% from the companys previous []

The heavy selling pressure might have exhausted for Ampio (AMPE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in r

The heavy selling pressure might have exhausted for Ampio (AMPE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in r

JPMorgan Chase & Co. purchased a new position in shares of Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 73,026 shares of the specialty pharmaceutical companys stock, valued at approximately $122,000. Other large investors have also added to or []

Ampio Pharmaceuticals, Inc. (AMPE) Q3 2021 Results - Earnings Call Transcript

ENGLEWOOD, Colo., Oct. 13, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflam